Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
29 hedge funds and large institutions have $14M invested in Allena Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
12% more funds holding
Funds holding: 26 → 29 (+3)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
65% less capital invested
Capital invested by funds: $39.5M → $14M (-$25.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$902K |
| 2 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
+$624K |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$569K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$354K |
| 5 |
Renaissance Technologies
New York
|
+$320K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.23M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$500K |
| 3 |
Millennium Management
New York
|
-$363K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$283K |
| 5 |
Goldman Sachs
New York
|
-$92K |
ALNA Hedge Fund Activity: Q1 2020 in Review
29 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q1 2020, worth a combined $14M — down 65% from $39.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ALNA positions and 4 closed out — a net gain of 4 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $902K. The largest seller was Deutsche Bank, exiting entirely with an estimated $1.23M sold.
- 29 institutional investors held Allena Pharmaceuticals (ALNA) as of Q1 2020, up from 26 in Q4 2019.
- Funds reported $14M of Allena Pharmaceuticals stock for Q1 2020, down 65% quarter-over-quarter.
- 8 funds opened new Allena Pharmaceuticals positions in Q1 2020 and 4 closed out, a net change of +4 holders.
- The largest Allena Pharmaceuticals buyer in Q1 2020 was Morgan Stanley, an estimated $902K added.
- The largest Allena Pharmaceuticals seller in Q1 2020 was Deutsche Bank, an estimated $1.23M sold.
Based on aggregated 13F filings for Q1 2020.